antihemorroidal cinfa

Hydrocortisone acetate	25 mg
Neomycin (sulphate)	3.5 mg
Benzocaine	45
Tannic acid	10 mg

Excipients: buthyl parahydroxybenzoate, 1.7 mg; methyl parahydroxybenzoate, 0.2 mg; cholesterol, 4.8 mg; microcrystalline wax, 38.8 mg; hard paraffin, 710.5 mg; liquid paraffin, 189.0 mg.

The association of hydrocortisone (a corticosteroid ingredient with a topic anti-inflammatory and anti-allergic action), neomycin (a wide spectrum antibiotic), tannic acid (an astringent, haemostatic agent) and benzocaine (an anesthetic, anti-itching) makes an efficient formula for the symptomatic treatment of the troubles caused by hemorrhoids.

Indications:

External and internal hemorrhoids, fissures, fistulas, ulcers, anal itching, etc.

Dosage:

In general three or four daily applications are recommended, using if needed, the cannula enclosed.

Contraindications - WARNINGS:

Those patients receiving corticosteroids by oral or parenteral tract and patients needing a long-term treatment, must follow their doctor's prescription,

This drug contains an active principle that may show a positive result on a doping test, so sportsman/women should be take this fact into account.

INCOMPATIBILITIES - Interactions:

Not described.

Side effects:

Not described.

Intoxication and treatment:

There is not clinical experience of severe intoxications.

Presentation:

30 g tube with an adaptable cannula.

MEDICINES SHOULD BE KEPT OUT OF THE REACH OF CHILDREN

MARKETING HOLDER/COMMERCIALISED BY:

LABORATORIES CINFA, S.A.
Olaz Chipi, 10, P.I. ARETA, 31,620 HUARTE-PAMPLONA, SPAIN.



Laboratorios Cinfa, S.A. Olaz Chipi 10 Huarte Pamplona ESPAGNE-SPAIN